Previous 10 | Next 10 |
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS -<span class="legendSpanClass">Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 -</span> -<span class="leg...
HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL PR Newswire SAN DIEGO , Feb. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth ...
Halozyme Therapeutics (NASDAQ:HALO) promoted Nicole LaBrosse to the position of senior vice president and CFO, effective immediately. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity. LaBrosse joined Halozyme in 2015, and since 2020 served as vice...
Halozyme Appoints New Chief Financial Officer PR Newswire SAN DIEGO , Feb. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial...
Sony Interactive Entertainment (NYSE: SONY) , revealed plans to acquire video game developer Bungie for a total of USD3.6 Billion. Bungie, which was previously acquired by Microsoft in 2000 before parting ways, is the company behind popular video games, Destiny and Halo. ...
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK - 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue - - 2022 Recurring Revenue from Royalties Projected to Grow by Approximately 50% over Record Royalties in 2021 to Appro...
Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference PR Newswire SAN DIEGO , Jan. 4, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief execut...
The U.S. equity market breathed a sigh of relief on Dec. 16 after the U.S. Federal Reserve disclosed its plans for reduced monthly bond-buying and increased interest rates for 2022. The central bank's aggressive stance on managing the stickier-than-expected inflation can prove to be a ...
Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +37%, Biofrontera BFRI +20%, ABVC BioPharma (NASDAQ:ABVC) +12%, Halozyme Therapeutics (NASDAQ:HALO) +11%, Context Therapeutics CNTX +9%. Losers: Angion Biomedica (NASDAQ:ANGN) -22%, Ensysce Biosciences ...
Halozyme Therapeutics (NASDAQ:HALO) has announced a new share repurchase program to buyback up to $750M of its outstanding common stock over the next three years. The program follows the recent completion of the company's previous $550M three-year share repurchase program. The biopharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...